Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Europe Vaccines Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991550
Published Content info 392 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Vaccines Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 392 Pages
Description

Europe vaccines market is projected to register a healthy CAGR of 6.5% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation

Europe Vaccines Market, By Composition (Combination Vaccines, Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines), Kind (Routine Vaccine, Recommended Vaccine, Required Vaccine), Age of Administration (Pediatric Vaccine, Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, Others), Route of Administration (Injectable, Oral, Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of the vaccines market are:

  • Increasing Awareness for Vaccination.
  • Launch of Newer Vaccines.

Market Players

The key market players for the vaccines market are listed below:

  • Emergent BioSolutions Inc.
  • Dynavax Technologies
  • Valneva SE
  • Bavarian Nordic
  • Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
  • Takeda Pharmaceutical Company Limited
  • Seqirus (a Subsidiary of CSL Limited),
  • Abbott
  • AstraZeneca
  • Sanofi
  • Pfizer Inc.
  • Janssen Europe Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
  • F. Hoffmann-La Roche Ltd
  • DAIICHI SANKYO COMPANY, LIMITED
  • ALK
  • Panacea Biotec Ltd
  • BAXTER VACCINES (a subsidiary of Baxter)
  • GlaxoSmithKline plc.
  • Serum Institute of India Pvt. Ltd.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF EUROPE VACCINES MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 COMPOSITION LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS

7 EUROPE VACCINES MARKET: LAWS AND REGULATIONS

8 EUROPE VACCINES MARKET: LOGISTICS OF VACCINES

8.1 COLD CHAIN STORAGE:

  • 8.2 REGULATIONS ASSOCIATED WITH VACCINE SUPPLY
  • 8.3 PROCESS OF LOGISTICS
  • 8.4 CHALLENGES IN LOGISTICS

8.5 CHALLENGES FACED BY INDIA FOR UPCOMING COVID 19 VACCINE:

8.6 CHALLENGES FACED BY LATIN AMERICA FOR UPCOMING VACCINE:

8.7 CHALLENGES FACED BY NIGERIA FOR VACCINE LOGISTICS:

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
    • 9.1.2 HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES
    • 9.1.3 IMPROVEMENT IN TREATMENT
    • 9.1.4 LAUNCH OF NEWER VACCINES
    • 9.1.5 INCREASING GOVERNMENT SUPPORT
  • 9.2 RESTRAINTS
    • 9.2.1 UNAVAILABILITY OF REGISTERED VACCINES
    • 9.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES
    • 9.2.3 DIFFICULTIES ASSOCIATED WITH TRANSPORT AND PRODUCTION OF VACCINES
  • 9.3 OPPORTUNITIES
    • 9.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
    • 9.3.2 PRESENCE OF PIPELINE PRODUCTS
    • 9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
    • 9.3.4 INCREASING AWARENESS FOR VACCINATION
  • 9.4 CHALLENGES
    • 9.4.1 SIDE EFFECTS CAUSED BY VACCINES
    • 9.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
    • 9.4.3 PRODUCT RECALL

10 IMPACT OF COVID-19 ON EUROPE VACCINES MARKET

  • 10.1 PRICE IMPACT
  • 10.2 IMPACT ON SUPPLY CHAIN
  • 10.3 IMPACT ON DEMAND
  • 10.4 CONCLUSION

11 EUROPE VACCINES MARKET, BY COMPOSITION

  • 11.1 OVERVIEW
  • 11.2 COMBINATION VACCINES
  • 11.3 MONO VACCINES

12 EUROPE VACCINES MARKET, BY TYPE

  • 12.1 OVERVIEW
  • 12.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
    • 12.2.1 PNEUMOCOCCAL DISEASE
    • 12.2.2 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
    • 12.2.3 HPV (HUMAN PAPILLOMA VIRUS)
    • 12.2.4 HEPATITIS B
    • 12.2.5 MENINGOCOCCAL
    • 12.2.6 SHINGLES
    • 12.2.7 WHOOPING COUGH
    • 12.2.8 OTHERS
  • 12.3 LIVE-ATTENUTAED VACCINES
    • 12.3.1 ROTAVIRUS
    • 12.3.2 MEASLES
    • 12.3.3 MUMPS
    • 12.3.4 RUBELLA
    • 12.3.5 SMALLPOX
    • 12.3.6 YELLOW FEVER
    • 12.3.7 OTHERS
  • 12.4 INACTIVATED VACCINES
    • 12.4.1 FLU (SHOT ONLY)
    • 12.4.2 POLIO (SHOT ONLY)
    • 12.4.3 HEPATITIS A
    • 12.4.4 RABIES
    • 12.4.5 OTHERS
  • 12.5 TOXOID VACCINES
    • 12.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
    • 12.5.2 OTHERS
  • 12.6 DNA VACCINES

13 EUROPE VACCINES MARKET, BY KIND

  • 13.1 OVERVIEW
  • 13.2 ROUTINE VACCINE
    • 13.2.1 PNEUMOCOCCAL
    • 13.2.2 DIPHTHERIA
    • 13.2.3 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
    • 13.2.4 MEASLES
    • 13.2.5 MUMPS
    • 13.2.6 HEPATITIS B
    • 13.2.7 RUBELLA
    • 13.2.8 POLIO
    • 13.2.9 OTHERS
  • 13.3 RECOMMENDED VACCINES
    • 13.3.1 TYPHOID FEVER VACCINES
    • 13.3.2 HEPATITIS A
    • 13.3.3 RABIES
    • 13.3.4 JAPANESE ENCEPHALITIS
    • 13.3.5 TICK-BORNE ENCEPHALITIS
    • 13.3.6 CHOLERA
    • 13.3.7 OTHERS
  • 13.4 REQUIRED VACCINES
    • 13.4.1 MENINGOCOCCAL
    • 13.4.2 YELLOW FEVER
    • 13.4.3 OTHERS

14 EUROPE VACCINES MARKET, BY AGE OF ADMINISTRATION

  • 14.1 OVERVIEW
  • 14.2 PEDIATRIC VACCINES
    • 14.2.1 PNEUMOCOCCAL
    • 14.2.2 MEASLES, MUMPS, AND, RUBELLA
    • 14.2.3 DIPHTHERIA, TETANUS & PERTUSIS (DPT)
    • 14.2.4 ROTAVIRUS
    • 14.2.5 MENINGOCOCCAL
    • 14.2.6 VARICELLA
    • 14.2.7 POLIO
    • 14.2.8 TUBERCULOSIS
    • 14.2.9 MALARIA
    • 14.2.10 OTHERS
  • 14.3 ADULT VACCINES
    • 14.3.1 INLFUENZA
    • 14.3.2 HPV (HUMAN PAPILLOMA VIRUS)
    • 14.3.3 TYPHOID
    • 14.3.4 HEPATITIS B
    • 14.3.5 JAPANESE ENCEPHALITIS
    • 14.3.6 YELLOW FEVER
    • 14.3.7 HIV
    • 14.3.8 CANCER
    • 14.3.9 OTHERS

15 EUROPE VACCINES MARKET, BY DISEASES

  • 15.1 OVERVIEW
  • 15.2 PNEUMOCCOCAL DISEASE
  • 15.3 MEASLES, MUMPS & RUBELLA
  • 15.4 DPT
  • 15.5 HEPATITIS
  • 15.6 INFLUENZA
  • 15.7 TYPHOID
  • 15.8 MENINGOCOCCAL
  • 15.9 VARICELLA
  • 15.10 RABIES
  • 15.11 JAPANESE ENCEPHALITIS
  • 15.12 YELLOW FEVER
  • 15.13 OTHERS

16 EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 16.1 OVERVIEW
  • 16.2 INJECTABLE
    • 16.2.1 INTRAMUSCULAR
    • 16.2.2 SUBCUTANEOUS
    • 16.2.3 INTRADERMAL
  • 16.3 ORAL
  • 16.4 NASAL

17 EUROPE VACCINES MARKET, BY END USER

  • 17.1 OVERVIEW
  • 17.2 COMMUNITY HOSPITALS
  • 17.3 HOSPITALS
  • 17.4 SPECIALTY CENTRES
  • 17.5 CLINICS
  • 17.6 OTHERS

18 EUROPE VACCINES MARKET, BY DISTRIBUTION CHANNEL

  • 18.1 OVERVIEW
  • 18.2 HOSPITAL PHARMACY
  • 18.3 RETAIL PHARMACY
  • 18.4 ONLINE PHARMACY

19 EUROPE VACCINES MARKET, BY GEOGRAPHY

  • 19.1 EUROPE
    • 19.1.1 GERMANY
    • 19.1.2 FRANCE
    • 19.1.3 U.K.
    • 19.1.4 ITALY
    • 19.1.5 SPAIN
    • 19.1.6 NETHERLAND
    • 19.1.7 RUSSIA
    • 19.1.8 SWITZERLAND
    • 19.1.9 TURKEY
    • 19.1.10 AUSTRIA
    • 19.1.11 NORWAY
    • 19.1.12 HUNGARY
    • 19.1.13 LITHUANIA
    • 19.1.14 IRELAND
    • 19.1.15 POLAND
    • 19.1.16 REST OF EUROPE

20 EUROPE VACCINES MARKET: COMPANY LANDSCAPE

  • 20.1 COMPANY SHARE ANALYSIS: EUROPE

21 COMPANY PROFILE

  • 21.1 GLAXOSMITHKLINE PLC.
    • 21.1.1 COMPANY SNAPSHOT
    • 21.1.2 REVENUE ANALYSIS
    • 21.1.3 COMPANY SHARE ANALYSIS
    • 21.1.4 PRODUCT PORTFOLIO
    • 21.1.5 RECENT DEVELOPMENTS
    • 21.1.6 SWOT ANALYSIS
  • 21.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 21.2.1 COMPANY SNAPSHOT
    • 21.2.2 REVENUE ANALYSIS
    • 21.2.3 COMPANY SHARE ANALYSIS
    • 21.2.4 PRODUCT PORTFOLIO
    • 21.2.5 RECENT DEVELOPMENTS
    • 21.2.6 SWOT ANALYS
  • 21.3 SANOFI
    • 21.3.1 COMPANY SNAPSHOT
    • 21.3.2 REVENUE ANALYSIS
    • 21.3.3 COMPANY SHARE ANALYSIS
    • 21.3.4 PRODUCT PORTFOLIO
    • 21.3.5 RECENT DEVELOPMENTS
    • 21.3.6 SWOT ANALYS
  • 21.4 PFIZER INC.
    • 21.4.1 COMPANY SNAPSHOT
    • 21.4.2 REVENUE ANALYSIS
    • 21.4.3 COMPANY SHARE ANALYSIS
    • 21.4.4 PRODUCT PORTFOLIO
    • 21.4.5 RECENT DEVELOPMENTS
    • 21.4.6 SWOT ANAL
  • 21.5 ABBOTT
    • 21.5.1 COMPANY SNAPSHOT
    • 21.5.2 REVENUE ANALYSIS
    • 21.5.3 COMPANY SHARE ANALYSIS
    • 21.5.4 PRODUCT PORTFOLIO
    • 21.5.5 RECENT DEVELOPMENTS
  • 21.6 ALK
    • 21.6.1 COMPANY SNAPSHOT
    • 21.6.2 REVENUE ANALYSIS
    • 21.6.3 PRODUCT PORTFOLIO
    • 21.6.4 RECENT DEVELOPMENTS
  • 21.7 ALTIMMUNE
    • 21.7.1 COMPANY SNAPSHOT
    • 21.7.2 REVENUE ANALYSIS
    • 21.7.3 PRODUCT PORTFOLIO
    • 21.7.4 RECENT DEVELOPMENTS
  • 21.8 ASTRAZENECA
    • 21.8.1 COMPANY SNAPSHOT
    • 21.8.2 REVENUE ANALYSIS
    • 21.8.3 PRODUCT PORTFOLIO
    • 21.8.4 RECENT DEVELOPMENTS
  • 21.9 BAVARIAN NORDIC
    • 21.9.1 COMPANY SNAPSHOT
    • 21.9.2 REVENUE ANALYSIS
    • 21.9.3 PRODUCT PORTFOLIO
    • 21.9.4 RECENT DEVELOPMENTS
  • 21.10 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
    • 21.10.1 COMPANY SNAPSHOT
    • 21.10.2 REVENUE ANALYSIS
    • 21.10.3 PRODUCT PORTFOLIO
    • 21.10.4 RECENT DEVELOPMENTS
  • 21.11 BHARAT BIOTECH
    • 21.11.1 COMPANY SNAPSHOT
    • 21.11.2 PRODUCT PORTFOLIO
    • 21.11.3 RECENT DEVELOPMENTS
  • 21.12 BIO FARMA
    • 21.12.1 COMPANY SNAPSHOT
    • 21.12.2 PRODUCT PORTFOLIO
    • 21.12.3 RECENT DEVELOPMENTS
  • 21.13 BIOLOGICAL E LIMITED
    • 21.13.1 COMPANY SNAPSHOT
    • 21.13.2 PRODUCT PORTFOLIO
    • 21.13.3 RECENT DEVELOPMENTS
  • 21.14 DAIICHI SANKYO COMPANY, LIMITED
    • 21.14.1 COMPANY SNAPSHOT
    • 21.14.2 REVENUE ANALYSIS
    • 21.14.3 PRODUCT PORTFOLIO
    • 21.14.4 RECENT DEVELOPMENTS
  • 21.15 DYNAVAX TECHNOLOGIES
    • 21.15.1 COMPANY SNAPSHOT
    • 21.15.2 REVENUE ANALYSIS
    • 21.15.3 PRODUCT PORTFOLIO
    • 21.15.4 RECENT DEVELOPMENTS
  • 21.16 EMERGENT BIOSOLUTIONS INC.
    • 21.16.1 COMPANY SNAPSHOT
    • 21.16.2 REVENUE ANALYSIS
    • 21.16.3 PRODUCT PORTFOLIO
    • 21.16.4 RECENT DEVELOPMENTS
  • 21.17 F. HOFFMANN-LA ROCHE LTD
    • 21.17.1 COMPANY SNAPSHOT
    • 21.17.2 REVENUE ANALYSIS
    • 21.17.3 PRODUCT PORTFOLIO
    • 21.17.4 RECENT DEVELOPMENT
  • 21.18 JANSSEN EUROPE SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 21.18.1 COMPANY SNAPSHOT
    • 21.18.2 REVENUE ANALYSIS
    • 21.18.3 PRODUCT PORTFOLIO
    • 21.18.4 RECENT DEVELOPMENTS
  • 21.19 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
    • 21.19.1 COMPANY SNAPSHOT
    • 21.19.2 PRODUCT PORTFOLIO
    • 21.19.3 RECENT DEVELOPMENTS
  • 21.20 PANACEA BIOTEC LTD
    • 21.20.1 COMPANY SNAPSHOT
    • 21.20.2 REVENUE ANALYSIS
    • 21.20.3 PRODUCT PORTFOLIO
    • 21.20.4 RECENT DEVELOPMENTS
  • 21.21 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
    • 21.21.1 COMPANY SNAPSHOT
    • 21.21.2 REVENUE ANALYSIS
    • 21.21.3 PRODUCT PORTFOLIO
    • 21.21.4 RECENT DEVELOPMENTS
    • 21.21.5 SWOT ANALYSIS
  • 21.22 SERUM INSTITUTE OF INDIA PVT. LTD.
    • 21.22.1 COMPANY SNAPSHOT
    • 21.22.2 PRODUCT PORTFOLIO
    • 21.22.3 RECENT DEVELOPMENTS
  • 21.23 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 21.23.1 COMPANY SNAPSHOT
    • 21.23.2 REVENUE ANALYSIS
    • 21.23.3 PRODUCT PORTFOLIO
    • 21.23.4 RECENT DEVELOPMENTS
  • 21.24 VALNEVA SE
    • 21.24.1 COMPANY SNAPSHOT
    • 21.24.2 REVENUE ANALYSIS
    • 21.24.3 PRODUCT PORTFOLIO
    • 21.24.4 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 EUROPE VACCINES MARKET: SEGMENTATION
  • FIGURE 2 EUROPE VACCINES MARKET : DATA TRIANGULATION
  • FIGURE 3 EUROPE VACCINES MARKET: DROC ANALYSIS
  • FIGURE 4 EUROPE VACCINES MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 EUROPE VACCINES MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 EUROPE VACCINES MARKET: MULTIVARIATE MODELLING
  • FIGURE 7 EUROPE VACCINES MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 8 EUROPE VACCINES MARKET: DBMR MARKET POSITION GRID
  • FIGURE 9 EUROPE VACCINES MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 10 EUROPE VACCINES MARKET: SEGMENTATION
  • FIGURE 11 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE EUROPE VACCINES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE VACCINES MARKET IN 2021 & 2028
  • FIGURE 13 FDA REGULATORY REVIEW PROCESS OF VACCINES
  • FIGURE 14 AEFI ORGANIZATIONAL STRUCTURES
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE VACCINES MARKET
  • FIGURE 16 EUROPE VACCINATION COVERAGE IN THE WORLD (2019)
  • FIGURE 17 PEDIATRIC DEATHS CAUSED BY INFLUENZA IN THE U.S. (2017 - 2020)
  • FIGURE 18 EUROPE PREVALENCE OF HBV INFECTION WORLDWIDE IN 2018
  • FIGURE 19 HEALTHCARE EXPENDITURE PER CAPITA, 2018
  • FIGURE 20 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
  • FIGURE 21 EUROPE VACCINES MARKET: BY COMPOSITION, 2021
  • FIGURE 22 EUROPE VACCINES MARKET: BY COMPOSITION, 2019-2028 (USD MILLION)
  • FIGURE 23 EUROPE VACCINES MARKET: BY COMPOSITION, CAGR (2021-2028)
  • FIGURE 24 EUROPE VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
  • FIGURE 25 EUROPE VACCINES MARKET: BY TYPE, 2021
  • FIGURE 26 EUROPE VACCINES MARKET: BY TYPE, 2019-2028 (USD MILLION)
  • FIGURE 27 EUROPE VACCINES MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 28 EUROPE VACCINES MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 29 EUROPE VACCINES MARKET: BY KIND, 2019
  • FIGURE 30 EUROPE VACCINES MARKET: BY KIND, 2019-2028 (USD MILLION)
  • FIGURE 31 EUROPE VACCINES MARKET: BY KIND, CAGR (2021-2028)
  • FIGURE 32 EUROPE VACCINES MARKET: BY KIND, LIFELINE CURVE
  • FIGURE 33 EUROPE VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019
  • FIGURE 34 EUROPE VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • FIGURE 35 EUROPE VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2021-2028)
  • FIGURE 36 EUROPE VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 37 EUROPE VACCINES MARKET: BY DISEASES, 2020
  • FIGURE 38 EUROPE VACCINES MARKET: BY DISEASES, 2019-2028 (USD MILLION)
  • FIGURE 39 EUROPE VACCINES MARKET: BY DISEASES, CAGR (2021-2028)
  • FIGURE 40 EUROPE VACCINES MARKET: BY DISEASES, LIFELINE CURVE
  • FIGURE 41 EUROPE VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019
  • FIGURE 42 EUROPE VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • FIGURE 43 EUROPE VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
  • FIGURE 44 EUROPE VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 45 EUROPE VACCINES MARKET: BY END USER, 2019
  • FIGURE 46 EUROPE VACCINES MARKET: BY END USER, 2019-2028 (USD MILLION)
  • FIGURE 47 EUROPE VACCINES MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 48 EUROPE VACCINES MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 49 EUROPE VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019
  • FIGURE 50 EUROPE VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • FIGURE 51 EUROPE VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 52 EUROPE VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 53 EUROPE VACCINES MARKET: SNAPSHOT (2020)
  • FIGURE 54 EUROPE VACCINES MARKET: BY COUNTRY (2020)
  • FIGURE 55 EUROPE VACCINES MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 56 EUROPE VACCINES MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 57 EUROPE VACCINES MARKET: BY TYPE (2021-2028)
  • FIGURE 58 EUROPE VACCINES MARKET: COMPANY SHARE 2020 (%)
Back to Top